Uveitis treatment well on its way to approval

The EMEA committee for Orphan Medicinal Products has adopted a positive opinion on orphan medicinal product designation for Isotechnika's ISA247, a treatment for chronic, non-infectious uveitis.

The EMEA committee for Orphan Medicinal Products has adopted a positive opinion on orphan medicinal product designation for Isotechnika's ISA247, a treatment for chronic, non-infectious uveitis.

Lux Biosciences, which has an exclusive worldwide license for ISA247 in ophthalmic indications, began enrolling subjects into three pivotal clinical trials earlier this year. Collectively known as LUMINATE, the trials represent the most comprehensive clinical programme ever undertaken in the field of uveitis.

The US FDA has already granted fast track designation to the drug.

Related Videos
Noninfectious uveitis, uveitic macular oedema: A synopsis of frontline therapies
Approaches for managing treatment of patients with endophthalmitis
ARMOR study: Evaluating antibiotic resistance in the treatment of staph infections
Investigating efficacy of OC-02 to stimulate the trigeminal nerve for the treatment of dry eyes
Related Content
© 2023 MJH Life Sciences

All rights reserved.